Biology

Virology

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Neutralizing antibody

Coronavirus disease 2019 (COVID-19)

Strain (injury)

Genetics

Monoclonal antibody

Anatomy

Binding site

Infectious disease (medical specialty)

Medicine

Virus

Disease

Immunoglobulin light chain

Antibody

Neutralization

Pathology

Cell

Terminating the SARS-CoV-2 pandemic relies upon pan-global vaccination. Current vaccines elicit neutralizing antibody responses to the virus spike derived from early isolates. However, new strains have emerged with multiple mutations, including P.1 from Brazil, B.1.351 from South Africa, and B.1.1.7 from the UK (12, 10, and 9 changes in the spike, respectively). All have mutations in the ACE2 binding site, with P.1 and B.1.351 having a virtually identical triplet (E484K, K417N/T, and N501Y), which we show confer similar increased affinity for ACE2. We show that, surprisingly, P.1 is significantly less resistant to naturally acquired or vaccine-induced antibody responses than B.1.351, suggesting that changes outside the receptor-binding domain (RBD) impact neutralization. Monoclonal antibody (mAb) 222 neutralizes all three variants despite interacting with two of the ACE2-binding site mutations. We explain this through structural analysis and use the 222 light chain to largely restore neutralization potency to a major class of public antibodies.

Antibody evasion by the P.1 strain of SARS-CoV-2